Trump's Funding Cuts Impact Harvard's Tuberculosis Research

Researchers affected by funding withdrawals are voicing concerns about potential long-term effects, yet some maintain that universities should still stand firm against federal directives.

Dr. Sarah Fortune, a prominent immunologist based at Harvard, finds herself unexpectedly entangled in a direct conflict with White House policies.

Early one Tuesday, she was instructed to halt her federally funded tuberculosis research—a disease noted for its high mortality rate worldwide. This came just as the Trump administration finalized a $2.2 billion funding freeze targeting Harvard, part of its broader initiative against top-tier universities since January's presidential transition.

The pause affected Dr. Fortune's $60 million NIH contract involving multiple universities, marking one of the initial projects impacted. Additional halt notices have surfaced at Harvard's 'sponsored programs' office, which manages federal research allocations.

Professor David R. Walt at Harvard also received a suspension notice, pausing his efforts to develop a diagnostic kit for Lou Gehrig’s disease, alias A.L.S. Other researchers faced similar setbacks in areas like space exploration, following governmental requests for expanded efforts in artificial organ research.